Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: Transplant Cell Ther. 2022 Feb 23;28(5):251–257. doi: 10.1016/j.jtct.2022.02.017

Table 4:

allo-SCT characteristics

All N = 15 (%)
Disease status post CAR T-Cell
CR 6 (40)
PR 9 (60)
Disease status at transplantation
CR 5 (33)
PR 7 (47)
PD 3 (20)
Donor type
Matched sibling 6 (40)
Matched unrelated 7 (47)
Haplo 2 (13)
Disease
DLBCL 10 (67)
PMBCL 2 (13)
Richter 2 (13)
DHL 1 (7)
GVHD
acute 5 (33)
chronic 1 (6)
Response
CR 9 (60)
PR 4 (27)
PD 1 (6)
Not evaluable 1 (6)
Death
Disease related 4
alloSCT related 3

Abbreviations:

CR- Complete Response

PR – Partial Response

PD – Progressive Disease

DLBCL – Diffuse large B Cell Lymphomas

PMBCL – Primary Mediastinal B Cell Lymphoma

DHL – Double Hit Lymphoma

GVHD – Graft Versus Host Disease

HSCT

alloSCT – Allogeneic Stem Cell Transplantation